Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.
Patients with IPF and emphysema who received antifibrotic agents had similar outcomes to patients with IPF alone.
The Food and Drug Administration has granted Breakthrough Therapy designation to CD388 for seasonal influenza prevention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback